Rocket Pharmaceuticals
RCKT
150 hedge funds and large institutions have $2.74B invested in Rocket Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 66 increasing their positions, 50 reducing their positions, and 32 closing their positions.
59% more call options, than puts
Call options by funds: $8.36M | Put options by funds: $5.25M
32% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 50
0% less capital invested
Capital invested by funds: $2.75B → $2.74B (-$13.7M)
2.72% less ownership
Funds ownership: 100.4% → 97.68% (-2.7%)
13% less funds holding
Funds holding: 173 → 150 (-23)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
69% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 32
Top Buyers
| 1 |
CAC
Cowen and Company
New York
|
+$43.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$24.3M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$18M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.9M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$8.21M |
Top Sellers
| 1 |
RI
RTW Investments
New York
|
-$31.5M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$17.4M |
| 3 |
Goldman Sachs
New York
|
-$16.1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.7M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$8.69M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IC
176
Ikarian Capital
Dallas,
Texas
| – | -$61K | -1,400 | Closed |
|
177
Simplex Trading
Chicago,
Illinois
| – | -$58.6K | -1,350 | Closed |
|
|
LC
178
Lindbrook Capital
Calabasas,
California
| – | -$10K | -236 | Closed |
|
|
GWS
179
Glassman Wealth Services
Vienna,
Virginia
| – | -$2.35K | -54 | -96% |
|
|
MWP
180
Meridian Wealth Partners
Exton,
Pennsylvania
| – | -$1K | -36 | Closed |
|
|
TFO
181
Tarbox Family Office
Newport Beach,
California
| – | -$1K | -19 | Closed |
|
|
IA
182
IFP Advisors
Tampa,
Florida
| – | -$651 | -15 | Closed |
|
RCKT Hedge Fund Activity: Q2 2021 in Review
150 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2021, worth a combined $2.74B — down 0.5% from $2.75B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of RCKT and 10 opened new positions — a net loss of 22 holders — while 50 trimmed existing stakes and 66 added.
The largest buyer was Cowen and Company, opening a new position worth an estimated $43.4M. The largest seller was RTW Investments, cutting an estimated $31.5M.
- 150 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2021, down from 173 in Q1 2021.
- Funds reported $2.74B of Rocket Pharmaceuticals stock for Q2 2021, down 0.5% quarter-over-quarter.
- 10 funds opened new Rocket Pharmaceuticals positions in Q2 2021 and 32 closed out, a net change of -22 holders.
- The largest Rocket Pharmaceuticals buyer in Q2 2021 was Cowen and Company, an estimated $43.4M added.
- The largest Rocket Pharmaceuticals seller in Q2 2021 was RTW Investments, an estimated $31.5M sold.
Based on aggregated 13F filings for Q2 2021.